Skip to main content

Table 1 Participant demographic and clinical characteristics

From: AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2

Sociodemographic and clinical characteristics

Mild/moderate COVID-19

n = 52

Sex

 Male, n (%)

30 (58%)

 Female, n (%)

22 (42%)

Age in years

 Median (range)

36 (22–42)

Days from laboratory-confirmed SARS-CoV-2 diagnosis to enrolment

 First wave, n; median (IQR)

30; 70 (59–87)

 Second wave, n; median (IQR)

22; 63 (39–71)

COVID-19 severity

 aMild

28 (54%)

 bModerate

19 (37%)

 Missing data

5 (9%)

Comorbidities (diabetes, hypertension or HIV)

 Yes

8 (15%)

 No

44 (85%)

  1. aPositive SARS-CoV-2 PCR without evidence of viral pneumonia or hypoxia
  2. bPositive SARS-CoV-2 PCR with clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) but no signs of severe pneumonia, including SpO2 > 89% on room air
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us